November 2025: A Month of Surprises and Setbacks in Endocrinology
While the world might have been gearing up for the holidays, the field of endocrinology was quietly buzzing with developments that could shape the future of diabetes, obesity, and beyond. But here's where it gets controversial: some of these advancements raise more questions than answers, leaving us wondering about the future of certain treatments and their potential impact on patients.
Sure, November 2025 didn't see any major approvals from the FDA, but that doesn't mean it was a dull month. GLP-1 receptor agonists (GLP-1 RAs), those powerhouse drugs initially developed for diabetes, continued their march into new territories like nephrology and cardiology, showcasing their versatility. And this is the part most people miss: while these drugs are showing promise in diverse areas, their long-term effects and optimal applications are still being meticulously studied.
Novo Nordisk, a major player in this field, experienced a rollercoaster ride. Their semaglutide, a GLP-1 RA, failed to significantly slow the progression of Alzheimer's disease, a disappointing outcome given the urgent need for effective treatments. However, their amycretin, another GLP-1 RA, demonstrated impressive weight loss results in patients with type 2 diabetes (T2D), outperforming placebo and sparking hope for a new obesity management tool.
The HCPLive editorial team has curated five must-read headlines from November 2025, offering a glimpse into the exciting and sometimes contradictory world of endocrinology research:
1. Amycretin: A New Weight Loss Champion for T2D?
Novo Nordisk's amycretin, administered either weekly subcutaneously or daily orally, emerged as a potential game-changer in a phase 2 trial. It not only triggered significant weight loss but also reduced HbA1c levels in T2D patients, paving the way for a phase 3 program in 2026. This dual benefit of weight management and glycemic control could be a major breakthrough for individuals struggling with both conditions.
2. Eloralintide: Targeting Obesity with Precision
Eloralintide, a once-weekly amylin receptor agonist, demonstrated superior weight reduction compared to placebo in adults with obesity and at least one weight-related health issue. Its ability to curb calorie intake, potentially by influencing feelings of fullness, makes it a promising candidate for obesity management. Ongoing trials are investigating its effectiveness both as a standalone treatment and in combination with tirzepatide for individuals with overweight, obesity, and T2D.
3. Semaglutide: Beyond Diabetes, Protecting the Heart and Kidneys
A meta-analysis revealed a surprising benefit of semaglutide: it reduces the risk of major cardiovascular events, kidney complications, and cardiovascular mortality in patients with chronic kidney disease (CKD), regardless of diabetes status. This finding underscores the need to explore the broader applications of GLP-1 RAs in nephrology, potentially offering new hope to a wider patient population.
4. Diabetes Dialogue: Tech Advances and Pricing Shifts
The latest episode of Diabetes Dialogue delved into two significant developments. Firstly, Dexcom's new G7 sensor, boasting a 15-day lifespan and seamless integration with existing apps, promises enhanced convenience and accuracy for diabetes management. Secondly, the discussion highlighted the substantial price reductions for Ozempic and Wegovy, making these medications more accessible to patients.
5. Semaglutide's Alzheimer's Setback and Tirzepatide's T1D Promise
While semaglutide failed to slow Alzheimer's progression in two phase 3 trials, leading to the discontinuation of a planned extension, tirzepatide showed promising results in the TIRTLE phase 2 trial. It demonstrated weight loss benefits, improved glycemic control, and reduced insulin requirements in adults with type 1 diabetes (T1D), offering a glimmer of hope for this patient population.
The Future of Endocrinology: Questions and Possibilities
November 2025's endocrinology news paints a picture of a field in flux, with both triumphs and setbacks. The expanding role of GLP-1 RAs, the search for effective Alzheimer's treatments, and the ongoing quest for better diabetes management all highlight the complexity and urgency of these challenges.
What do you think? Are GLP-1 RAs the future of treating multiple conditions, or are we placing too much hope in a single class of drugs? Will we see a breakthrough in Alzheimer's treatment soon, or is the disease still too complex to crack? Share your thoughts in the comments below!
Stay informed about the latest advancements in endocrinology and beyond by subscribing to HCPLive's newsletter. Join thousands of clinicians and healthcare professionals who rely on HCPLive for cutting-edge research, expert insights, and essential updates.
